Antibody responses in oral fluid after administration of prophylactic human papillomavirus vaccines.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 19698077.
- Also identified by DOI 10.1086/606026 and PMC identifier 3392559.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We sought to determine whether oral fluid can be used to assess serum human papillomavirus (HPV) antibody status by enrolling women who had received a prophylactic HPV-16 vaccine in a new follow-up study. After the prophylactic HPV-6/11/16/18 vaccine was licensed in the United States, we administered it to consenting participants. With serologic findings used as the reference standard, The sensitivity of oral fluid was 49.6% (95% confidence interval [CI], 42.0%-57.3%) before and 100% (95% CI, 92.0%-100%) after administration of the quadrivalent vaccine. Oral fluid may have the potential to be used for monitoring of prophylactic HPV vaccines in the future.
Medical subject headings
- Antibodies, Viral
- Exudates and Transudates
- Human papillomavirus 16
- Immunoglobulin G
- Papillomavirus Vaccines